This site is intended for US healthcare professionals only.

    Get to the core

    Overall
    response rate
    (ORR)*

    25.3%

    (95% CI:
    16.4-36.0)

    For Adult Patients With
    Relapsed Refractory Multiple Myeloma (RRMM)
    With the first and only FDA-approved oral XPO1 inhibitor1
    XPOVIO® (selinexor) + dexamethasone demonstrated clinically significant responses in adult patients with RRMM whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab (N=83).
    *Includes stringent complete response (sCR) + complete response (CR) + very good partial response (VGPR) + partial response (PR). ORR as assessed by an Independent Review Committee (IRC) based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma was the primary efficacy endpoint in the STORM Part 2 clinical trial.

    Reference: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; July 2019.